HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients

SOUTH SAN FRANCISCO, Calif.,– March 21, 2024– Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials